Please assess the completion status of the following clinical trial:

Trial Title: Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute coronary syndromes~* Pretreatment (2 hours) with high loading dose (600 mg) clopidogrel~* Significant angiographic lesions amenable to and requiring a PCI~* Written informed consent~Exclusion Criteria:~* ST-segment elevation acute myocardial infarction within 48 hours from symptom onset~* Hemodynamic instability~* Pericarditis~* Malignancies with life expectancy less than one year~* Increased risk of bleeding~* Oral anticoagulation therapy with coumarin derivative within 7 days~* Recent use of GPIIb/IIIa inhibitors within 14 days~* Severe uncontrolled hypertension \>180 mmHg unresponsive to therapy~* Relevant hematologic deviations: hemoglobin \< 100g/L or hematocrit \< 34%; platelet count \< 100 x 10\^9/L or platelet count \> 600 x 10\^9/L.~* Known allergy to the study medication~* Pregnancy (present or suspected)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).